Literature DB >> 21210795

Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.

Noah C Godwin1, James H Willig, Christa R Nevin, Hui-Yi Lin, Jeroan Allison, Kathy Gaddis, Jennifer Peterson, Michael S Saag, Michael J Mugavero, James L Raper.   

Abstract

BACKGROUND: The AIDS Drug Assistance Program (ADAP) provides antiretroviral medications to low-income individuals with HIV infection.
METHODS: A prospective cohort study of ADAP utilization, measured using medication possession ratio (MPR), was conducted during the 2008 calendar year at the University of Alabama at Birmingham 1917 HIV Clinic. Multivariable ordinal logistic regression evaluated factors associated with ADAP utilization.
RESULTS: Among 245 patients, MPR quartiles (Q) were the following: Q1<69 percent, Q2=69-83 percent, Q3=84-93 percent, Q4>93 percent. In ordinal logistic regression, younger age (OR=0.59 per 10 years; 95 percent CI=0.44-0.79), nonwhite males (2.18; 1.18-4.04), lower CD4 count (2.79 for <200 cells/mm(3) ; 1.44-5.43), and a history of alcohol abuse (2.11; 1.02-4.37) were associated with poor ADAP utilization.
CONCLUSIONS: One quarter of ADAP enrollees had MPR below 69 percent, a level well below that associated with optimal HIV treatment outcomes, indicating a need for programmatic interventions to improve ADAP utilization. © Health Research and Educational Trust.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21210795      PMCID： PMC3097412          DOI： 10.1111/j.1475-6773.2010.01223.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN： 0017-9124            Impact factor:   3.402


  30 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

Review 2.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

3.  Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status.

Authors:  Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula
Journal:  Health Psychol       Date:  2007-01       Impact factor: 4.267

4.  Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults.

Authors:  Jean B Nachega; Michael Hislop; David W Dowdy; Melanie Lo; Saad B Omer; Leon Regensberg; Richard E Chaisson; Gary Maartens
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

5.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

6.  Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Authors:  Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

7.  The therapeutic implications of timely linkage and early retention in HIV care.

Authors:  Kimberly B Ulett; James H Willig; Hui-Yi Lin; Justin S Routman; Sarah Abroms; Jeroan Allison; Ashlee Chatham; James L Raper; Michael S Saag; Michael J Mugavero
Journal:  AIDS Patient Care STDS       Date:  2009-01       Impact factor: 5.078

8.  Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.

Authors:  Anna Conen; Jan Fehr; Tracy R Glass; Hansjakob Furrer; Rainer Weber; Pietro Vernazza; Bernard Hirschel; Matthias Cavassini; Enos Bernasconi; Heiner C Bucher; Manuel Battegay
Journal:  Antivir Ther       Date:  2009

9.  Failure to establish HIV care: characterizing the "no show" phenomenon.

Authors:  Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; James H Willig; Pei-Wen Chang; Malcolm Marler; James L Raper; Joseph E Schumacher; Maria Pisu; Michael S Saag
Journal:  Clin Infect Dis       Date:  2007-05-23       Impact factor: 9.079

Review 10.  The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Authors:  J A Cramer; A Benedict; N Muszbek; A Keskinaslan; Z M Khan
Journal:  Int J Clin Pract       Date:  2007-11-05       Impact factor: 2.503
View more
  5 in total

1.  Personalized therapeutics: a potential threat to health equity.

Authors:  Michael M Ward
Journal:  J Gen Intern Med       Date:  2012-02-07       Impact factor: 5.128

2.  A qualitative study of underutilization of the AIDS drug assistance program.

Authors:  Kristin M Olson; Noah C Godwin; Sara Anne Wilkins; Michael J Mugavero; Linda D Moneyham; Larry Z Slater; James L Raper
Journal:  J Assoc Nurses AIDS Care       Date:  2014-02-04       Impact factor: 1.354

3.  Characterization of the Population Affected by the 6-Month Recertification Criterion of the Ryan White HIV/AIDS Program's AIDS Drug Assistance Program in Washington State, 2017-2019.

Authors:  Steven Erly; Christine M Khosropour; Anjum Hajat; Monisha Sharma; Jen Reuer; Martha Grimm; Kelse Kwaiser; Julia C Dombrowski
Journal:  J Acquir Immune Defic Syndr       Date:  2022-01-01       Impact factor: 3.771

4.  Determinants of utilization of a no-cost HIV transition clinic: a cross-sectional study of young adults living with HIV/AIDS.

Authors:  Agnes Nyabigambo; Joshua Kanaabi Muliira; Lynn Atuyambe; Harriet M Babikako; Andrew Kambugu; Christopher Ndoleriire
Journal:  Adolesc Health Med Ther       Date:  2014-05-29

5.  Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.

Authors:  David B Hanna; Kate Buchacz; Kelly A Gebo; Nancy A Hessol; Michael A Horberg; Lisa P Jacobson; Gregory D Kirk; Mari M Kitahata; P Todd Korthuis; Richard D Moore; Sonia Napravnik; Pragna Patel; Michael J Silverberg; Timothy R Sterling; James H Willig; Ann Collier; Hasina Samji; Jennifer E Thorne; Keri N Althoff; Jeffrey N Martin; Benigno Rodriguez; Elizabeth A Stuart; Stephen J Gange
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.